RNA hybrid-capture next-generation sequencing has high sensitivity in identifying known and less characterized oncogenic and likely oncogenic NTRK fusions in a real-world standard-of-care setting

In this study, we analyzed over 19,000 solid tumor samples using DNA and RNA hybrid-capture sequencing as part of routine clinical care. Our findings highlight that RNA-based next-generation sequencing is a highly sensitive approach for detecting both known and novel  NTRK fusions—rare but actionable alterations that can guide targeted therapy across multiple tumor types.